Cutaneous leukocytoclastic vasculitis in a patient with myelodysplatic syndrome after therapy with the rapamycin analogue everlimus: Case report and review of the literature

Leukemia and Lymphoma

Volumn 47, Issue 5, 2006, Pages 926-929

  Yee, Karen W L ^a   Hymes, Sharon R ^b   Heller, Lior ^a   Prieto, Victor G ^a   Welch, Mary Alma ^a   Giles, Francis J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIHISTAMINIC AGENT; CALCITRIOL; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; DEFEROXAMINE MESYLATE; DEXTROPROPOXYPHENE; ERYTHROPOIETIN; EVEROLIMUS; FUROSEMIDE; GLIBENCLAMIDE; HYDROXYZINE; LANOLIN ALCOHOL; LENALIDOMIDE; METFORMIN; RAPAMYCIN DERIVATIVE; SU 541; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VITAMIN D DERIVATIVE;

AGED; ARTICLE; CASE REPORT; DEBRIDEMENT; DRUG ERUPTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; LEUKOCYTOCLASTIC VASCULITIS; MYELODYSPLASTIC SYNDROME; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SKIN BIOPSY; WOUND INFECTION;

AGED; FEMALE; HUMANS; MYELODYSPLASTIC SYNDROMES; SIROLIMUS; SKIN; VASCULITIS, HYPERSENSITIVITY;

EID: 33744945302     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500399870     Document Type: Article

References (19)

1. Panwalkar, A and Vertovsek, S and Giles, F. (2004) Mammalian target of rapamycin inhibition as therapy for hematologic malignancies Cancer, 100, pp. 657-666.
2. Yee, K and Wierda, W and O'Brien, S and Thomas, D and Kurzrock, R and Fayad, L and et al (2004) A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies Blood, 104, pp. 287b.
3. Sais, G and Vidaller, A and Jucglà, A and Servitje, O and Condom, E and Peyri, J. (1998) Prognostic factors in leukocytoclastic vasculitis. A clinicopathologic study of 160 patients Archives of Dermatology, 134, pp. 309-315.
4. Crowson, A and Mihm, M, Jr and Magro, C. (2003) Cutaneous vasculitis: A review Journal of Cutaneous Pathology, 30, pp. 161-173.
5. Hardinger, K and Cornelius, L and Trulock, E, 3rd and Brennan, D. (2002) Sirolimus-induced leukocytoclastic vasculitis Transplantation, 74, pp. 739-743.
6. Pasqualotto, A and Bianco, P and Sukiennik, T and Furian, R and Garcia, V. (2004) Sirolimus-induced leukocytoclastic vasculitis: The second case reported American Journal of Transplants, 4, pp. 1549-1551.
7. Schaffellner, S and Jakoby, E and Kniepeiss, D and Stadlbauer, V and Duller, D and Iberer, F and Tscheliessnigg, K. (2005) Center experience in liver transplantation (LTX): Management of dermal side effects caused by sirolimus International Immunopharmacology, 5, pp. 137-140.
8. Nagarajan, S and Friedrich, T and Garcia, M and Kambham, N and Sarwal, M. (2005) Gastrointestinal leukocytoclastic vasculitis: An adverse effect of sirolimus Pediatric Transplants, 9, pp. 97-100.
9. Pirayesh, A and Verbunt, R and Kluin, P and Meinders, A and De Meijer, P. (1997) Myelodysplastic syndrome with vasculitis manifestations Journal of Internal Medicine, 242, pp. 425-431.
10. Hamblin, T. (1992) Immunologic abnormalities in myelodysplastic syndromes Hematology & Oncology Clinics of North America, 6, pp. 571-586.
11. Okamoto, T and Okada, M and Mori, A and Saheki, K and Takatsuka, H and Wada, H and et al (1997) Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients International Journal of Hematology, 66, pp. 345-351.
12. Kahan, B and Wong, R and Carter, C and Katz, S and Von Fellenberg, J and Van Buren, C and Appel-Dingemanse, S. (1999) A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients Transplantation, 68, pp. 1100-1106.
13. Recher, C and Beyne-Rauzy, O and Demur, C and Chicanne, G and Dos Santos, C and Mas, V and et al (2005) Anti-leukemic activity of rapamycin in acute myeloid leukemia Blood, 105, pp. 2527-2534.
14. Platzbecker, U and Haase, M and Herbst, R and Hanel, A and Voigtmann, K and Thiede, C and et al (2005) Activity of sirolimus in patients with myelodysplastic syndrome - results of a pilot study British Journal of Haematology, 128, pp. 625-630.
15. Pascual, J and Marcen, R and Ortuno, J. (2005) Clinical experience with everolimus (Certican): Optimizing dose and tolerability Transplantation, 79, pp. S80-S84.
16. Hardinger, K and Cornelius, L and Trulock, E, 3rd and Brennan, D. (2002) Sirolimus-induced leukocytoclastic vasculitis Transplantation, 74, pp. 739-743.
17. Pasqualotto, A and Bianco, P and Sukiennik, T and Furian, R and Garcia, V. (2004) Sirolimus-induced leukocytoclastic vasculitis: The second case reported American Journal of Transplants, 4, pp. 1549-1551.
18. Schaffellner, S and Jakoby, E and Kniepeiss, D and Stadlbauer, V and Duller, D and Iberer, F and Tscheliessnigg, K. (2005) Center experience in liver transplantation (LTX): Management of dermal side effects caused by sirolimus International Immunophamacology, 5, pp. 137-140.
19. Nagarajan, S and Friedrich, T and Garcia, M and Kambham, N and Sarwal, M. (2005) Gastrointestinal leukocytoclastic vasculitis: An adverse effect of sirolimus Pediatric Transplants, 9, pp. 97-100.